AJJ Medtech’s FY2025 annual report shows a few notable changes: revenue growth, a sharp improvement in gross profit, and a narrower net loss. Management and the controlling shareholder also continued to provide support.
The bigger point is that AJJ is increasingly framing itself as more than a conventional medtech distributor.
This video breaks down the key numbers, the support signal, and the platform story behind HIT-1. Watch the video for the full picture.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments